☰

Abarceo Pharma AB

Digital infrastructure for a biotech spin-out

A Swedish Lund University spin-out developing the VDAC1 platform for Type 2 Diabetes and Alzheimer's

Industry
Pharmaceutical Biotechnology
Headquarters
Lund, Sweden
Public information as of
January 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of Abarceo Pharma AB's published strategy and is not endorsed by, or produced in cooperation with, Abarceo Pharma AB. Company website

Strategic priorities

Abarceo Pharma is a Swedish biotech company spun out from the Lund University Diabetes Centre, advancing the VDAC1 mitochondrial repair mechanism as a novel therapeutic approach targeting Type 2 Diabetes, Alzheimer's disease, and cardiovascular conditions. The VDAC1 programme is built on the scientific foundation of the founder's research into how mitochondrial dysfunction contributes to metabolic disease — a platform that has attracted the interest of global pharmaceutical companies including Eli Lilly and Biogen.

The strategic challenge is the transition from an academic research environment to an industrial drug development organisation: conducting R&D in-house at Medeon Science Park with a small team of PhD researchers, while simultaneously preparing for the data integrity standards that global pharmaceutical partners require. The company must demonstrate 21 CFR Part 11 compliance, maintain rigorous audit trails, and provide partners with real-time visibility into development progress.

Abarceo operates with the infrastructure constraints of a small research organisation — standalone Industrial PCs, paper notebooks, and manual Excel-based data workflows — while needing to meet the regulatory and data governance standards of a pharmaceutical partnership. The gap between current capabilities and partner expectations is the primary digital transformation challenge.

Challenges we see

  • Operations Manufacturing

    Small team managing complex mitochondrial assay workflows manually

    Abarceo's strategic decision to conduct R&D in-house at Medeon with a small team of PhD researchers creates significant operational pressure as the VDAC1 programme advances toward Phase 1 trials. Manual execution of mitochondrial assays and cell culture management will face throughput limitations as the company accelerates its development timeline.

    When the same scientists who are designing experiments and interpreting results must also manually track samples, manage reagent inventory, and maintain paper notebooks, the throughput of the laboratory is constrained by administrative capacity rather than by scientific capability.

  • Digital Integration

    VDAC1 research data scattered across disconnected Excel workbooks

    Research into VDAC1 mitochondrial biology generates high-dimensional data from molecular modelling, genetic sequencing, and real-time mitochondrial activity monitoring — all tracked in separate Excel workbooks on local drives, with no unified analysis platform and no connection to the ELN or LIMS.

    When research data is scattered across Excel workbooks on individual computers, the cross-experiment analysis required to identify patterns in mitochondrial response is limited by the scientists' ability to manually reconcile and compare data from different files — missing the patterns that a unified data platform would surface automatically.

  • Compliance Regulatory

    Academic-to-industrial transition creating data integrity standards gap

    Transitioning from academic research to FDA and EMA-compliant drug development requires rigorous audit trails, validated digital environments, and the documentation discipline that pharmaceutical regulators expect. Academic research norms — rapid iteration, flexibility in data recording — are not sufficient for the regulatory expectations of clinical development.

    When global pharmaceutical partners conduct due diligence on Abarceo's data practices, they find a laboratory that operates closer to academic norms than to pharmaceutical GMP standards — the data integrity gap is a blocker to the partnership agreements that Abarceo needs to fund Phase 1 development.

  • Digital Integration

    Legacy data systems from university spin-out transition

    As an academic spin-out, Abarceo inherited legacy data formats, equipment protocols, and software tools from the university laboratory — including proprietary data formats from discontinued software, undocumented assay procedures, and local storage practices that were adequate for academic publication but insufficient for pharmaceutical development.

    When Abarceo tries to consolidate and migrate the legacy data from the university spin-out period, the absence of documentation for data formats and the reliance on discontinued software creates a data rescue problem that requires specialist intervention to solve.

  • Operations Operations

    Single hardware failures risking loss of critical experimental data

    Small research facilities typically operate with standalone Industrial PCs controlling laboratory equipment — each PC is a single point of failure for the experiment it controls. A hardware failure during a long-duration cell culture study could mean the loss of weeks or months of experimental work.

    When a cell culture study is running on an experiment PC that is not backed up and not monitored, a hardware failure means the study must be repeated from the beginning — the experimental timeline is set back by the duration of the lost culture period, with associated cost and delay.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. Real-time bioprocess KPI visualisation for mitochondrial assay monitoring

    Scientists analyse experimental data retrospectively after experiment conclusion, unable to monitor beta-cell reversion processes in real time or compare against optimal parameters during execution — missing the intervention window that would prevent an experiment from producing off-target results.

    Implement real-time KPI visualisation dashboards with Golden Batch overlay capabilities for the mitochondrial assay workflows — enabling scientists to monitor live experimental data against optimal parameter profiles and make intervention decisions during execution rather than after the data is collected.

    • Abarceo Pharma mitochondrial assay protocols and data flow assessment
    • Current experimental data review timeline analysis

  2. Ontology-driven data platform for VDAC1 biological research

    Critical biological KPIs and mitochondrial research data are tracked in fragmented Excel workbooks separate from live process trends — preventing the unified cross-experiment analysis required to identify patterns in mitochondrial response across the VDAC1 programme.

    Deploy an ontology-driven Industrial Data Platform that unifies molecular, genetic, and clinical data into a machine-readable ecosystem — enabling AI and ML applications in drug discovery and providing the cross-experiment analysis capability that the current Excel-based workflow cannot support.

    • Abarceo Pharma data architecture assessment
    • VDAC1 programme data volume and complexity analysis

  3. Digital lab onboarding and change management for academic researchers

    Academic researchers transitioning to industrial R&D data practices experience 'Black Box Anxiety' toward automated data pipelines and AI-driven insights — defaulting to manual workarounds that replicate academic habits rather than adopting the digital workflows that pharmaceutical development requires.

    Implement structured digital onboarding programmes with sandbox environments that build researcher confidence in automated data pipelines and the ontology platform — eliminating the manual workarounds that prevent the digital infrastructure from delivering its intended value.

    • Abarceo Pharma researcher digital readiness assessment
    • Current manual data workflow documentation

  4. Partner-grade data integrity and transparency for Eli Lilly and Biogen

    Global pharmaceutical partners including Eli Lilly and Biogen require high data integrity standards, reproducibility, and auditability that Abarceo's current paper-based systems cannot demonstrate — the gap between Abarceo's data practices and partner expectations is a blocker for high-value collaboration agreements.

    Modernise laboratory infrastructure using vendor-agnostic integration and MTP standards to provide pharmaceutical partners with real-time transparency and high-fidelity data packages that meet the standards required for co-development agreements — removing the data integrity blocker from partnership discussions.

    • Abarceo Pharma partnership due diligence requirements
    • 21 CFR Part 11 and EMA data integrity requirements for pharmaceutical development

  5. High-availability infrastructure and Zero Trust security for research IP

    As the VDAC1 platform attracts international attention and Abarceo raises additional capital, the valuable intellectual property in the mitochondrial repair research becomes an attractive target for cyber threats — the current standalone PC infrastructure provides no security architecture and no resilience against hardware failure.

    Implement high-availability cluster architecture for the laboratory computing infrastructure and Zero Trust security controls that protect venture-funded research from cyber events — ensuring business continuity during the company's high-growth phase and demonstrating to partners that IP is protected.

    • Abarceo Pharma IT infrastructure assessment
    • VDAC1 IP valuation and threat model

What we'd propose

  • Digital Lab

    Real-Time Bioprocess Intelligence Platform

    We deploy Grafana-based real-time KPI visualisation dashboards for Abarceo Pharma's mitochondrial assay workflows — displaying live experimental data with Golden Batch comparison overlays, automated Bio-KPI calculations, and alert thresholds that notify scientists when an experiment is deviating from the optimal parameter profile.

    • Live mitochondrial activity monitoring dashboard

      Beta-cell assay parameters visible in real time during experiments

      Deploy real-time monitoring dashboards connected to the mitochondrial assay equipment — displaying oxygen consumption rate, mitochondrial membrane potential, and ATP production rate as live traces that scientists can review during experiment execution rather than waiting for post-run data analysis.

    • Golden Batch reference profiles for key assays

      Every experiment compared to the best historical performance

      Build Golden Batch reference profiles for the key VDAC1 programme assays — enabling scientists to compare any in-progress experiment against the best historical performance and identify when the current experiment is trending toward a suboptimal outcome.

    • Automated experimental alert system

      Scientists alerted when experiments deviate from optimal parameters

      Configure automated alerts that notify the responsible scientist via email and dashboard when any monitored parameter exceeds the configured deviation threshold — ensuring that experiment deviations are caught during execution rather than discovered in post-run analysis.

    • Scientists identify and address experiment deviations during execution rather than after the data is collected — the number of experiments that produce off-target results due to mid-run parameter drift decreases.
    • The Golden Batch reference profiles encode institutional knowledge about what good experimental conditions look like — this knowledge is preserved and made accessible even as individual scientists leave or change roles.
    • The alert system ensures that no experiment deviation goes unnoticed — the scientific team's attention is directed to the experiments that need it rather than being spread evenly across all ongoing work.

    We've done this before

    See how we do Digital Lab
  • Enterprise AI

    Ontology-Driven VDAC1 Research Data Platform

    We build an ontology-driven data platform tailored for Abarceo Pharma's mitochondrial biology research — unifying molecular modelling data, genetic sequencing results, and real-time mitochondrial activity monitoring into a machine-readable ecosystem that enables AI and ML applications and provides the cross-experiment analysis capability that the current Excel-based workflow cannot support.

    • Research data ontology for mitochondrial biology

      VDAC1 data organised in a biologically meaningful structure

      Define the ontology that structures Abarceo Pharma's research data — connecting genetic sequences, protein expression measurements, mitochondrial activity assays, and clinical outcomes in a biologically meaningful framework that enables queries across data types without manual reconciliation.

    • Automated data ingestion from assay instruments

      Data flows from instruments to the platform automatically

      Deploy automated data ingestion pipelines from the mitochondrial assay instruments and sequencers — eliminating the manual Excel-based data extraction step and ensuring that every experimental result is captured in the platform at the point of generation.

    • AI-ready data architecture for VDAC1 drug discovery

      Platform ready for ML model training on VDAC1 programme data

      Configure the data architecture so that the platform outputs are in the format required for ML model training — the VDAC1 programme data is ready for AI-driven pattern recognition and biomarker discovery without additional data preparation steps.

    • Cross-experiment analysis that currently requires weeks of manual data reconciliation is available on demand — scientists can ask complex questions across the entire VDAC1 programme dataset and receive answers in hours.
    • The AI-ready data architecture means that when Abarceo Pharma is ready to apply machine learning to the VDAC1 programme, the infrastructure is already in place — the barrier to ML adoption is lower because the data foundation has been built.
    • The platform provides the evidence base for the pharmaceutical partnership data room — partner scientific teams can review Abarceo's research data through the platform rather than relying on PDFs and PowerPoints.

    We've done this before

    See how we do Enterprise AI
  • Digital Lab

    Digital Lab Integration with MTP Standards

    We implement Module Type Package standard integration for Abarceo Pharma's laboratory equipment — enabling plug-and-produce flexibility for new instruments, vendor-agnostic connectivity that prevents lock-in, and the equipment integration depth required to demonstrate pharmaceutical partner-grade data practices.

    • MTP-compliant equipment module library

      All laboratory instruments have MTP-compliant integration

      Define MTP-compliant equipment modules for the key instruments in the Abarceo Pharma laboratory — the Seahorse analyser, confocal microscope, and cell culture monitors — so that new equipment can be added to the platform without custom integration engineering.

    • Vendor-agnostic instrument connectivity layer

      No vendor lock-in for laboratory equipment

      Build a vendor-agnostic connectivity layer that connects all laboratory instruments to the research data platform regardless of vendor — eliminating the lock-in that comes from vendor-specific software and enabling Abarceo to upgrade or replace any instrument without breaking the data pipeline.

    • Partner data access portal

      Pharmaceutical partners access research data via a controlled portal

      Configure a controlled data access portal for pharmaceutical partners — providing real-time visibility into programme progress, experimental results, and assay data through role-based access that gives partners the transparency they require without exposing Abarceo's full intellectual property.

    • The MTP-compliant laboratory demonstrates to pharmaceutical partners that Abarceo Pharma operates with modern, standards-based laboratory infrastructure — the data practices are aligned with what partners expect from a co-development partner rather than from an academic research group.
    • The partner data portal removes the friction from partnership conversations — Abarceo can offer partners the data access they require without the security risk of unrestricted file sharing and without the overhead of manual data package preparation.
    • The vendor-agnostic connectivity layer protects the laboratory against vendor lock-in — as new instruments are added to the VDAC1 programme, they integrate with the platform rather than creating new data silos.

    We've done this before

    See how we do Digital Lab
  • Digital Lab

    Change Management and Digital Onboarding Programme

    We implement a structured digital transformation programme for Abarceo Pharma's research team — building researcher confidence in the ontology platform and automated data pipelines through sandbox environments, structured training, and a graduated adoption approach that makes digital workflows the natural choice rather than a mandatory requirement.

    • Sandbox environment for process simulation

      Researchers test new workflows without risking live data

      Deploy sandbox environments where researchers can explore the new data platform and ontology tools using anonymised sample data — building familiarity and confidence with the system before it is deployed for live experimental data.

    • Structured digital onboarding curriculum

      PhD researchers trained on platform in a structured programme

      Develop a structured onboarding programme for the research team that introduces the ontology platform, automated data pipelines, and digital workflow tools in graduated stages — starting with the most immediately useful capabilities and building from there.

    • Digital champion network

      Peer support from digitally confident researchers

      Identify and develop digital champions within the research team — researchers who are confident with the new tools and can provide peer support to colleagues who are still developing their digital workflows.

    • The change management programme reduces the risk that researchers default to their old Excel-based workflows after the platform is launched — the peer support from digital champions and the structured onboarding create genuine adoption rather than compliance.
    • The sandbox environment gives researchers the confidence to experiment with the new tools — they can see how the platform works with sample data before trusting it with their actual experimental results.
    • The digital champions become the internal advocates for the digital transformation — their enthusiasm and competence inspire their peers and create a positive feedback loop that accelerates adoption.

    We've done this before

    See how we do Digital Lab
  • Digital Lab

    High-Availability Infrastructure and Zero Trust Security Framework

    We modernise Abarceo Pharma's laboratory IT infrastructure with high-availability cluster architecture and Zero Trust security controls — protecting the VDAC1 intellectual property from cyber threats, eliminating single points of failure in critical experimental infrastructure, and demonstrating to pharmaceutical partners that the company's data governance is worthy of a co-development relationship.

    • High-availability cluster for laboratory computing

      No single point of failure for experimental computing

      Migrate the laboratory computing infrastructure to a high-availability cluster — ensuring that a hardware failure on any single node does not interrupt ongoing experiments or result in data loss for cell culture studies and long-duration assays.

    • Zero Trust network architecture for research IP

      VDAC1 research data protected by identity-aware access controls

      Implement Zero Trust network architecture — identity-aware proxies, device authentication, and microsegmentation — that protects the VDAC1 research data from unauthorised access while enabling legitimate researchers to access the data they need from any location.

    • Automated backup and disaster recovery for experimental data

      Every experimental result backed up continuously

      Configure automated backup and disaster recovery for all experimental data — ensuring that the data from long-duration cell culture studies is protected against both hardware failure and ransomware, with recovery time objectives that match the experimental timelines.

    • The VDAC1 intellectual property is protected by security controls that meet pharmaceutical partner standards — the partnership due diligence process finds a security posture that is appropriate for the value of the data being protected.
    • Hardware failures no longer threaten the continuity of long-duration cell culture studies — the high-availability cluster ensures that experimental data is protected and the study continues even if a node fails.
    • The automated disaster recovery provides protection against ransomware — the VDAC1 research data is recoverable from immutable backups even in the worst-case scenario of a complete site compromise.

    We've done this before

    See how we do Digital Lab

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what Abarceo Pharma AB's own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
Data Integration 25 → 85
VDAC1 research data is scattered across Excel workbooks on individual computers with no unified platform connecting molecular modelling, genetic sequencing, and mitochondrial activity monitoring. The ontology-driven data platform required for cross-experiment analysis has not been built.
Process Automation 30 → 80
Laboratory procedures rely on manual data extraction, paper notebooks, and manual Excel-based workflows. Automated data capture from instruments, the ontology platform, and the digital lab transformation required to support pharmaceutical partner data standards have not been implemented.
Regulatory Readiness 35 → 90
The transition from academic research practices to FDA and EMA-compliant drug development requires 21 CFR Part 11 controls, validated electronic records, and audit trail capability that the current paper-based system does not provide. The gap between current practices and partner expectations is the primary blocker for the Eli Lilly and Biogen partnership discussions.
Cybersecurity Posture 30 → 85
The standalone PC infrastructure provides no security architecture for the VDAC1 intellectual property. No Zero Trust controls, no security monitoring, and no automated backup are in place — the research data is vulnerable to both hardware failure and cyber intrusion.
Infrastructure Resilience 25 → 80
Each laboratory PC is a single point of failure for the experiment it controls. Long-duration cell culture studies can be lost entirely if the controlling PC fails. The high-availability cluster architecture required to eliminate these single points of failure has not been deployed.
Digital Culture 40 → 75
Academic researchers default to familiar manual workflows — paper notebooks, Excel, manual data transfer — rather than adopting the digital tools that the platform provides. The Black Box Anxiety toward automated data pipelines reflects a cultural gap that tool deployment alone cannot close.

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of January 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with Abarceo Pharma AB, and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].